Related Experiment Video

Updated: Aug 29, 2026

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery
09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

[Angiotensin-converting enzyme inhibitors :from vasoactive drugs to cardiovascular prevention tools]

Pietro Amedeo Modesti1, Simone Vanni, Gian Franco Gensini

  • 1Clinica Medica Generale e Cardiologia Università degli Studi Viale Morgagni, 85 50134 Firenze. pa.modesti@dfc.unifi.it

Italian Heart Journal. Supplement : Official Journal of the Italian Federation of Cardiology
|December 6, 2003
PubMed

Insights

Angiotensin-converting enzyme (ACE)-inhibitors significantly lower cardiovascular risks in heart failure and myocardial infarction patients. Their benefits extend to hypertensive patients with comorbidities, suggesting mechanisms beyond blood pressure control.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Hypertension Research

Context:

  • Angiotensin-converting enzyme (ACE)-inhibitors are established treatments for heart failure and myocardial infarction.
  • Recent evidence highlights their benefits in hypertensive patients with comorbidities.
  • Clinical indications for ACE-inhibitors have expanded due to these findings.

Purpose:

  • To review the established and emerging clinical benefits of ACE-inhibitors.
  • To explore the efficacy of ACE-inhibitors in hypertensive patients with comorbid conditions, particularly diabetes.
  • To investigate potential mechanisms of action beyond blood pressure reduction.

Summary:

  • ACE-inhibitors demonstrably reduce long-term cardiovascular morbidity and mortality in heart failure and myocardial infarction.
  • In severe hypertension, blood pressure control is the primary driver of risk reduction, irrespective of the specific antihypertensive agent.
  • In patients with comorbidities like diabetes, combining ACE-inhibitors with other antihypertensives enhances cardiovascular risk reduction, indicating non-hemodynamic effects.

Impact:

  • Reinforces the importance of ACE-inhibitors in managing cardiovascular diseases.
  • Suggests tailored therapeutic strategies for hypertensive patients with specific comorbidities.
  • Opens avenues for research into novel therapeutic targets and mechanisms of action for cardiovascular protection.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...